000125219 001__ 125219
000125219 005__ 20240228145518.0
000125219 0247_ $$2doi$$a10.1016/S1470-2045(17)30442-4
000125219 0247_ $$2pmid$$apmid:28677575
000125219 0247_ $$2ISSN$$a1470-2045
000125219 0247_ $$2ISSN$$a1474-5488
000125219 0247_ $$2altmetric$$aaltmetric:21401267
000125219 037__ $$aDKFZ-2017-01374
000125219 041__ $$aeng
000125219 082__ $$a610
000125219 1001_ $$aPearson, Andrew D J$$b0
000125219 245__ $$aFrom class waivers to precision medicine in paediatric oncology.
000125219 260__ $$aLondon$$bThe Lancet Publ. Group$$c2017
000125219 3367_ $$2DRIVER$$aarticle
000125219 3367_ $$2DataCite$$aOutput Types/Journal article
000125219 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1533036490_1957$$xReview Article
000125219 3367_ $$2BibTeX$$aARTICLE
000125219 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125219 3367_ $$00$$2EndNote$$aJournal Article
000125219 520__ $$aNew drugs are crucially needed for children with cancer. The European Paediatric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring in adults. In this Review, we retrospectively searched oncology drugs that were class waivered between June, 2012, and June, 2015. 147 oncology class waivers were confirmed for 89 drugs. Mechanisms of action were then assessed as potential paediatric therapeutic targets by both a literature search and an expert review. 48 (54%) of the 89 class-waivered drugs had a mechanisms of action warranting paediatric development. Two (2%) class-waivered drugs were considered not relevant and 16 (18%) required further data. In light of these results, we propose five initiatives: an aggregated database of paediatric biological tumour drug targets; molecular profiling of all paediatric tumours at diagnosis and relapse; a joint academic-pharmaceutical industry preclinical platform to help analyse the activity of new drugs (Innovative Therapy for Children with Cancer Paediatric Preclinical Proof-of-Concept Platform); paediatric strategy forums; and the suppression of article 11b of the European Paediatric Regulation, which allows product-specific waivers on the grounds that the associated condition does not occur in children. These initiatives and a mechanism of action-based approach to drug development will accelerate the delivery of new therapeutic drugs for front-line therapy for those children who have unmet medical needs.
000125219 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000125219 588__ $$aDataset connected to CrossRef, PubMed,
000125219 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b1
000125219 7001_ $$aBaruchel, Andre$$b2
000125219 7001_ $$aBourquin, Jean-Pierre$$b3
000125219 7001_ $$aCasanova, Michela$$b4
000125219 7001_ $$aChesler, Louis$$b5
000125219 7001_ $$aDoz, François$$b6
000125219 7001_ $$0P:(DE-HGF)0$$aEggert, Angelika$$b7
000125219 7001_ $$aGeoerger, Birgit$$b8
000125219 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b9
000125219 7001_ $$aKearns, Pamela R$$b10
000125219 7001_ $$aMolenaar, Jan J$$b11
000125219 7001_ $$aMorland, Bruce$$b12
000125219 7001_ $$aSchleiermacher, Gudrun$$b13
000125219 7001_ $$0P:(DE-He78)91317a47fc8532e3daf0d0b362c2a27e$$aSchulte, Johannes$$b14
000125219 7001_ $$aVormoor, Josef$$b15
000125219 7001_ $$aMarshall, Lynley V$$b16
000125219 7001_ $$aZwaan, C Michel$$b17
000125219 7001_ $$aVassal, Gilles$$b18
000125219 7001_ $$aConsortium, Executive and Biology Committees of the Innovative Therapies for Children with Cancer European$$b19$$eCollaboration Author
000125219 773__ $$0PERI:(DE-600)2035574-9$$a10.1016/S1470-2045(17)30442-4$$gVol. 18, no. 7, p. e394 - e404$$n7$$pe394 - e404$$tThe @lancet <London> / Oncology$$v18$$x1470-2045$$y2017
000125219 909CO $$ooai:inrepo02.dkfz.de:125219$$pVDB
000125219 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000125219 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000125219 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000125219 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)91317a47fc8532e3daf0d0b362c2a27e$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000125219 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000125219 9141_ $$y2017
000125219 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125219 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125219 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125219 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET ONCOL : 2015
000125219 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000125219 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000125219 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125219 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125219 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125219 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000125219 915__ $$0StatID:(DE-HGF)9925$$2StatID$$aIF >= 25$$bLANCET ONCOL : 2015
000125219 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000125219 9201_ $$0I:(DE-He78)L201-20160331$$kL201$$lDKTK Berlin$$x1
000125219 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000125219 980__ $$ajournal
000125219 980__ $$aVDB
000125219 980__ $$aI:(DE-He78)B062-20160331
000125219 980__ $$aI:(DE-He78)L201-20160331
000125219 980__ $$aI:(DE-He78)L101-20160331
000125219 980__ $$aUNRESTRICTED